HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction].

AbstractOBJECTIVES:
This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction.
METHODS:
A series of 100 consecutive patients (September 2004 to November 2005)with acute myocardial infarction undergoing primary stenting using SES ptember 24 hr) was compared with 100 consecutive patients (September 2003 to August 2004) treated with bare metal stent (BMS). The frequency of major adverse cardiac events (MACE) and stent thrombosis, and status of ticlopidine administration were assessed at 270 days.
RESULTS:
The rates of premature discontinuation of ticlopidine (SES group <3 months: 11%, BMS group <1 month: 11%, p = NS) and stent thrombosis (SES group: 1%, BMS group: 0%, p = NS) were similar in the two groups. At follow-up, restenosis rate and target vessel revascularization rate were lower in the SES group(4% vs 19%, p < 0.001 and 4% vs 10%, p = 0.149, respectively). Furthermore, the occurrence of MACE at 270 days was significantly less frequent in the SES group compared with the BMS group (6% vs. 17%, p = 0.038). Multivariate analysis showed SES use tended to predict 270-day MACE (hazard ratio 0.37, 95% confidence interval 0.14-1.02, p = 0.055). Culprit lesion located in the left main trunk was identified as an independent predictor of 270-day MACE (hazard ratio 5.43, 95% confidence interval 1.07-27.59, p = 0.041).
CONCLUSIONS:
The use of a SES was not associated with increased risk of stent thrombosis compared with a BMS. With lower rates of restenosis and subsequent target vessel revascularization, SES placement could provide superior outcomes in patients with acute myocardial infarction.
AuthorsTomoko Gochi, Hisashi Umeda, Naoki Yoshida, Hironobu Maekawa, Kosuke Watanabe, Taro Okada, Toshiaki Katoh, Toru Asai, Tomomitsu Tani, Masaki Yokoya, Yoshimasa Murakami, Toyoaki Matsushita, Takeshi Shimizu, Yukio Ozaki, Shinya Hiramitsu, Toyoaki Murohara, Masanori Nomura, Shinichiro Morimoto, Hitoshi Hishida
JournalJournal of cardiology (J Cardiol) Vol. 48 Issue 5 Pg. 253-61 (Nov 2006) ISSN: 0914-5087 [Print] Netherlands
PMID17136820 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Platelet Aggregation Inhibitors
  • Ticlopidine
  • Sirolimus
Topics
  • Aged
  • Coronary Restenosis (prevention & control)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (therapy)
  • Platelet Aggregation Inhibitors (administration & dosage)
  • Retrospective Studies
  • Sirolimus (administration & dosage)
  • Stents (adverse effects)
  • Ticlopidine (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: